title: Central effects of the angiotensin-converting enzyme inhibitor, captopril. I. Performance and subjective assessments of mood.
abstract: 1. Central effects of single doses of captopril (12.5, 25 and 50 mg) were studied in fourteen healthy male subjects. Two placebos and an active control drug, oxazepam (15 mg), were included, together with a single dose of atenolol (100 mg). The drugs were administered double-blind at 11.00 h, and performance and subjective feelings were assessed before and from 1.5-2.5 h and 3.5-4.5 h after ingestion. 2. Performance was assessed using digit symbol substitution, continuous attention, letter cancellation, choice reaction time, finger tapping, immediate and short-term memory, together with critical flicker fusion and two flash fusion. Subjects assessed their mood and well-being on a series of 12 visual analogue scales. 3. Captopril did not impair performance on any of the tests, but improved short-term memory (P less than 0.05) and increased the number of letters cancelled (P less than 0.05). Oxazepam reduced the number of substitutions completed in the digit symbol test (P less than 0.01), accuracy on continuous attention (P less than 0.05), number of letters cancelled (P less than 0.05), and rate of finger tapping (P less than 0.05), and increased choice reaction time (P less than 0.001). Atenolol reduced the rate of finger tapping (P less than 0.05), but increased the number of letters cancelled (P less than 0.05). 4. No effects on mood or on subjective feelings were evident with captopril. Oxazepam reduced subjective alertness (P less than 0.05), and atenolol increased feelings of sleepiness (P less than 0.05). 5. Although these observations suggest that central effects may exist with captopril, no adverse consequences have been established on performance or on subjective assessment of mood. Captopril may, therefore, be an appropriate drug for hypertensive patients engaged in skilled activity.
authors.affiliation: Department of Pharmacology and Clinical Pharmacology, Ninewells Hospital and Medical School, Dundee.
authors.forename: D
authors.initials: D
authors.lastname: Currie
authors.forename: R V
authors.initials: RV
authors.lastname: Lewis
authors.forename: D G
authors.initials: DG
authors.lastname: McDevitt
authors.forename: A N
authors.initials: AN
authors.lastname: Nicholson
authors.forename: N A
authors.initials: NA
authors.lastname: Wright
mesh_terms: D000328:Adult; D000339:Affect / Q000187:drug effects*; D001262:Atenolol / Q000009:adverse effects / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects; D002216:Captopril / Q000009:adverse effects* / Q000627:therapeutic use; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000503:physiopathology; D008297:Male; D010076:Oxazepam / Q000009:adverse effects / Q000627:therapeutic use; D011597:Psychomotor Performance / Q000187:drug effects*
chemical_list: D001262:Atenolol; D010076:Oxazepam; D002216:Captopril